Detalhe da pesquisa
1.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 375(14): 1319-1331, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27705267
2.
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Blood
; 128(14): 1821-1828, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27531679
3.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 380(9839): 358-65, 2012 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22735384
4.
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 13(11): 1087-95, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23051966
5.
Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Lancet Oncol
; 10(6): 549-58, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19428297
6.
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
J Clin Oncol
; 31(26): 3205-11, 2013 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23918947
7.
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
J Clin Oncol
; 27(32): 5363-9, 2009 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19805683